Table 2 Level of VEGF and PlGF in IVR group and IVA group
Ranibuzumab | Aflibercept | ||||||
|---|---|---|---|---|---|---|---|
pre | 1w | 1 M | pre | 1w | 1 M | ||
VEGF (pg/ml) | AC | 138.1 ± 25.8 | 58.5 ± 42.7* | 164.6 ± 28.3 | 4.8 ± 0.9** | ||
Plasma | 120.2 ± 11.3 | 137.4 ± 17.7 | 136.6 ± 13.0 | 93.7 ± 17.6 | 39.5 ± 11.6** | 64.3 ± 15.2* | |
PlGF (pg/ml) | AC | 5.8 ± 1.9 | 5.4 ± 0.9 | 5.1 ± 1.1 | 3.6 ± 1.0* | ||
Plasma | 3.7 ± 0.5 | 3.4 ± 0.4 | 3.4 ± 0.5 | 4.0 ± 0.5 | 5.6 ± 0.5** | 3.7 ± 0.4 | |